25 April 2025 – The European Medicines Agency (EMA) has recommended granting a marketing authorisation in the European Union (EU) for Tepezza (teprotumumab), for the treatment of adults. Tepezza is supposed to significantly improve symptoms for patients with moderate to severe thyroid eye disease (TED). TED is a rare autoimmune disease triggering inflammation of muscle, fat, and other tissues behind and around the eyes.

For more information, see here.